Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL01Antineoplastic agents
- Pharmacological subgroupL01E
- Chemical subgroupL01ED
- Chemical substanceL01ED01Crizotinib
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Spain
AEMPS · 5 registrations
- Xalkori 150 MG Granulado en Capsulas Para Abrir150 mg · granulado en capsulas para abrir · Pfizer Europe Ma Eeig
- Xalkori 20 MG Granulado en Capsulas Para Abrir20 mg · granulado en capsulas para abrir · Pfizer Europe Ma Eeig
- Xalkori 200 MG Capsulas Duras200,00 mg · cápsula dura · Pfizer Europe Ma Eeig
- Xalkori 250 MG Capsulas Duras250,00 mg · cápsula dura · Pfizer Europe Ma Eeig
Netherlands
CBG-MEB · 5 registrations
At a glance
- ATC code
- L01ED01
- Registers
- 10
- Historical lists
- 2
- Registrations
- 29
- With their own page
- 23
- Companies
- 9
All medicines with Crizotinib
Human medicines from every register that match Crizotinib by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
29 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Xalkori | United States | 200MG, 250MG | capsule | Marketed | PF Prism CV |
| Xalkori | United States | 150MG, 20MG, 50MG | capsule, pellets | Marketed | PF Prism CV |
| Xalkori 200 MG Capsulas Duras | Spain | 200,00 mg | cápsula dura | Marketed | Pfizer Europe Ma Eeig |
| Xalkori 250 MG Capsulas Duras | Spain | 250,00 mg | cápsula dura | Marketed | Pfizer Europe Ma Eeig |
| Xalkori 20 MG Granulado en Capsulas Para Abrir | Spain | 20 mg | granulado en capsulas para abrir | Marketed | Pfizer Europe Ma Eeig |
| Xalkori 50 MG Granulado en Capsulas Para Abrir | Spain | 50 mg | granulado en capsulas para abrir | Marketed | Pfizer Europe Ma Eeig |
| Xalkori 150 MG Granulado en Capsulas Para Abrir | Spain | 150 mg | granulado en capsulas para abrir | Marketed | Pfizer Europe Ma Eeig |
| Xalkori | European Union | Authorised | Pfizer Europe MA EEIG | ||
| XALKORI 200 mg, capsules, hard | Netherlands | Capsule, hard | Authorised | Pfizer Europe MA EEIG | |
| XALKORI 250 mg, capsules, hard | Netherlands | Capsule, hard | Authorised | Pfizer Europe MA EEIG | |
| Xalkori 20 mg, granulaat in capsules om te openen | Netherlands | Granulaat | Authorised | Pfizer Europe MA EEIG | |
| Xalkori 50 mg, granulaat in capsules om te openen | Netherlands | Granulaat | Authorised | Pfizer Europe MA EEIG | |
| Xalkori 150 mg, granulaat in capsules om te openen | Netherlands | Granulaat | Authorised | Pfizer Europe MA EEIG | |
| Xalkori | Canada | 200 MG | Capsule | Marketed | Pfizer Canada Ulc |
| Xalkori | Canada | 250 MG | Capsule | Marketed | Pfizer Canada Ulc |
| Xalkori Capsules 200mg | Singapore | 200 mg | capsule | Authorised | Pfizer Private Limited |
| Xalkori Capsules 250mg | Singapore | 250 mg | capsule | Authorised | Pfizer Private Limited |
| Xalkori | Brazil | Authorised | Pfizer Brasil Ltda | ||
| Xalkori® | Serbia | 250mg | kapsula, tvrda | Authorised | Pfizer SRB D.O.O. |
| Xalkori® | Serbia | 200mg | kapsula, tvrda | Authorised | Pfizer SRB D.O.O. |
| Xalkori | Croatia | Marketed | |||
| Xalkori | New Zealand | Cap 250 mg | Funded | ||
| Xalkori | New Zealand | Cap 200 mg | Funded | ||
| Xalkori 200MG Capsule | Saudi Arabia | Authorised | Pfizer | ||
| Xalkori 250MG Capsule | Saudi Arabia | Authorised | Pfizer |